Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF

Detalles Bibliográficos
Autores principales: Lehmacher, W., Klasser, M., Duering, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805708/
https://www.ncbi.nlm.nih.gov/pubmed/26860847
http://dx.doi.org/10.1007/s00520-016-3116-3
_version_ 1782423189596405760
author Lehmacher, W.
Klasser, M.
Duering, A.
author_facet Lehmacher, W.
Klasser, M.
Duering, A.
author_sort Lehmacher, W.
collection PubMed
description
format Online
Article
Text
id pubmed-4805708
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-48057082016-04-09 Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF Lehmacher, W. Klasser, M. Duering, A. Support Care Cancer Letter to the Editor Springer Berlin Heidelberg 2016-02-10 2016 /pmc/articles/PMC4805708/ /pubmed/26860847 http://dx.doi.org/10.1007/s00520-016-3116-3 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Lehmacher, W.
Klasser, M.
Duering, A.
Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title_full Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title_fullStr Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title_full_unstemmed Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title_short Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF
title_sort letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim—correction of a systematic review and meta-analysis of randomized controlled trials with g-csf
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805708/
https://www.ncbi.nlm.nih.gov/pubmed/26860847
http://dx.doi.org/10.1007/s00520-016-3116-3
work_keys_str_mv AT lehmacherw lettertotheeditornoincreasedfebrileneutropeniarisktocancerpatientsreceivinglipegfilgrastimcorrectionofasystematicreviewandmetaanalysisofrandomizedcontrolledtrialswithgcsf
AT klasserm lettertotheeditornoincreasedfebrileneutropeniarisktocancerpatientsreceivinglipegfilgrastimcorrectionofasystematicreviewandmetaanalysisofrandomizedcontrolledtrialswithgcsf
AT dueringa lettertotheeditornoincreasedfebrileneutropeniarisktocancerpatientsreceivinglipegfilgrastimcorrectionofasystematicreviewandmetaanalysisofrandomizedcontrolledtrialswithgcsf

Ejemplares similares